Prednisone in full dose
PreclinicalSmall molecule
Prednisone in full dose is one of 33 small molecule programs targeting IgA Nephropathy. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Iga Nephropathy
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Rituxan
RocheApproved
Lorelco
SanofiApproved
Fabhalta
NovartisApproved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Velcade
SShilpa Grover, MD, MPH
Approved
Kerendia
BayerPhase 3
Farxiga
AstraZenecaPhase 3
Filspari
TTravere Therapeutics, Inc.
Phase 3
Vanrafia
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Prednisone in full dose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- ZZhi-Hong Liu, M.D.